^
    Back
    Association details:
    Biomarker:ALK1 rearrangement
    Cancer:Thyroid Gland Anaplastic Carcinoma
    Drug:Xalkori (crizotinib) (ALK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    J Clin Oncol
    Title:

    Remarkable Response to Crizotinib in Woman With Anaplastic Lymphoma Kinase–Rearranged Anaplastic Thyroid Carcinoma

    Excerpt:
    A 71-year-old woman...The gross examination of the surgical specimen revealed a 36 × 27 mm nonencapsulated nodule of the right thyroid lobe….we found ALK1 overexpression...we found a rearrangement of the ALK1 gene...CT examination at baseline (Fig 3A) and at 3 months after crizotinib (Fig 3B) showed an exceptional response of more than 90%...
    DOI:
    10.1200/JCO.2013.49.6596